Clinical First-in-Human Single-Dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-Center, Phase I, Open-Label, i.v. Infusion Study.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zolbetuximab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; First in man
Sponsors Ganymed Pharmaceuticals

Most Recent Events

12 Jun 2018 Results published in the European Journal of Cancer.
12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
31 Aug 2017 According to a Astellas Pharma media release, new data from this study will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight